Table 1.
Description of new indicators of disease activity in inflammatory bowel disease (NIDA-IBD) cohort who were followed prospectively for 24 months.
| All IBD (n = 171) | CD (n = 99) | UC (n = 72) | |
|---|---|---|---|
| Median Age (IQR, years) | 46 (36-59) | 44 (34-57) | 48 (40-63) |
| Female participants (%) | 90 (52.6) | 52 (52.5) | 38 (52.8) |
| Median time since IBD diagnosis (range, years) | 13.0 (5.0-22.0) | 13.0 (6.0-21.0) | 11.5 (4.0-23.5) |
| European ethnicity (%) | 168 (98.2) | 99 (100) | 69 (95.8) |
| Montreal Classification of IBD(%) | |||
| A1 | 7 (7) | 0 (0) | |
| A2 | 74 (75) | 19 (26) | |
| A3 | 18 (18) | 53 (74) | |
| L1 | 17 (18) | ||
| L2 | 21 (21) | ||
| L3 | 61 (62) | ||
| B1 | 59 (60) | ||
| B2 | 20 (20) | ||
| B3 | 20 (20) | ||
| Perianal disease | 17 (17) | ||
| E1 | 6 (8.3) | ||
| E2 | 33 (45.8) | ||
| E3 | 33 (45.8) | ||
| Baseline corticosteroid use for IBD | 28 (16.4) | 12 (12.1) | 16 (22.2) |
| Corticosteroid use in the last year for IBD | 59 (34.5) | 33 (33.3) | 26 (36.1) |
| Baseline immunomodulator use for IBD | 67 (39.2) | 41 (41.4) | 26 (36.1) |
| Baseline use of biological agents for IBD | 37 (21.6) | 27 (27.3) | 10 (13.9) |
| History of depression | 17 (9.9) | 13 (13.1) | 4 (5.6) |
| History of anxiety | 13 (7.6) | 10 (10.1) | 3 (4.2) |
| History of concurrent irritable bowel syndrome | 11 (6.4) | 8 (8.1) | 3 (4.2) |
| Endoscopically active IBD (SES-CD >2, UCEIS ≥2, %) | 97 (56.7) | 62 (62.6) | 35 (48.6) |
| Endoscopically inactive/mildly active IBD (SES-CD <7, UCEIS<5, %) | 130 (76.0) | 71 (71.7) | 59 (81.9) |
| Active symptoms at baseline (HBI >4, SCCAI >5; %) |
96 (56.1) | 60 (60.6) | 36 (20.9) |
| Median fecal calprotectin (IQR, µg/g) | 132.7 (46.2-523.1) | 120.0 (46.2-353.5) | 146.1 (45.2-853.1) |
| Median fecal myeloperoxidase (IQR, µg/g) | 11.01 (2.43-61.12) | 10.40 (3.27-44.88) | 15.57 (1.66-107.46) |
| Median IBDQ-32 (IQR) | 169.0 (136.0-196.0) | 165.0 (132.0-195.0) | 177.0 (138.3-200.8) |
| Clinical relapse requiring biological/immunomodulator escalation at 24 months (%) | 45 (26.3) | 26 (26.3) | 19 (26.4) |
| Recurrent corticosteroid use at 24 months (%) | 25 (14.6) | 12 (12.1) | 13 (18.1) |
| IBD related hospitalization at 24 months (%) | 23 (13.5) | 16 (16.2) | 7 (9.7) |
| IBD related surgery at 24 months (%) | 17 (9.9) | 12 (12.1) | 5 (6.9) |
| Complicated IBD course 24 months (%) | 71 (41.5) | 45 (45.5) | 26 (36.1) |
Abbreviations: IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; Immunomodulator, thiopurine or methotrexate; SES-CD, simple endoscopic score for CD; UCEIS, ulcerative colitis endoscopic index of severity; HBI, Harvey-Bradshaw Index; CDAI, Crohn’s disease activity index; SCCAI, simple clinical colitis activity index; IBDQ-32, inflammatory bowel diseases questionnaire